Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

274 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit.
Noshi T, Kitano M, Taniguchi K, Yamamoto A, Omoto S, Baba K, Hashimoto T, Ishida K, Kushima Y, Hattori K, Kawai M, Yoshida R, Kobayashi M, Yoshinaga T, Sato A, Okamatsu M, Sakoda Y, Kida H, Shishido T, Naito A. Noshi T, et al. Among authors: omoto s. Antiviral Res. 2018 Dec;160:109-117. doi: 10.1016/j.antiviral.2018.10.008. Epub 2018 Oct 11. Antiviral Res. 2018. PMID: 30316915 Free article.
Treatment-Emergent Influenza Variant Viruses With Reduced Baloxavir Susceptibility: Impact on Clinical and Virologic Outcomes in Uncomplicated Influenza.
Uehara T, Hayden FG, Kawaguchi K, Omoto S, Hurt AC, De Jong MD, Hirotsu N, Sugaya N, Lee N, Baba K, Shishido T, Tsuchiya K, Portsmouth S, Kida H. Uehara T, et al. Among authors: omoto s. J Infect Dis. 2020 Jan 14;221(3):346-355. doi: 10.1093/infdis/jiz244. J Infect Dis. 2020. PMID: 31309975 Clinical Trial.
Comprehensive assessment of amino acid substitutions in the trimeric RNA polymerase complex of influenza A virus detected in clinical trials of baloxavir marboxil.
Hashimoto T, Baba K, Inoue K, Okane M, Hata S, Shishido T, Naito A, Wildum S, Omoto S. Hashimoto T, et al. Among authors: omoto s. Influenza Other Respir Viruses. 2021 May;15(3):389-395. doi: 10.1111/irv.12821. Epub 2020 Oct 24. Influenza Other Respir Viruses. 2021. PMID: 33099886 Free PMC article.
Evaluating the fitness of PA/I38T-substituted influenza A viruses with reduced baloxavir susceptibility in a competitive mixtures ferret model.
Lee LY, Zhou J, Koszalka P, Frise R, Farrukee R, Baba K, Miah S, Shishido T, Galiano M, Hashimoto T, Omoto S, Uehara T, Mifsud EJ, Collinson N, Kuhlbusch K, Clinch B, Wildum S, Barclay WS, Hurt AC. Lee LY, et al. Among authors: omoto s. PLoS Pathog. 2021 May 6;17(5):e1009527. doi: 10.1371/journal.ppat.1009527. eCollection 2021 May. PLoS Pathog. 2021. PMID: 33956888 Free PMC article.
A strategy for neuraminidase inhibitors using mechanism-based labeling information.
Hinou H, Miyoshi R, Takasu Y, Kai H, Kurogochi M, Arioka S, Gao XD, Miura N, Fujitani N, Omoto S, Yoshinaga T, Fujiwara T, Noshi T, Togame H, Takemoto H, Nishimura S. Hinou H, et al. Among authors: omoto s. Chem Asian J. 2011 Apr 4;6(4):1048-56. doi: 10.1002/asia.201000594. Epub 2011 Feb 8. Chem Asian J. 2011. PMID: 21305698
Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: An interim report of phase 2/3, randomized, observer-blinded, noninferiority study.
Shinkai M, Sonoyama T, Kamitani A, Shibata RY, Seki NM, Omoto S, Shinoda M, Sato T, Ishii N, Igarashi K, Ariyasu M. Shinkai M, et al. Among authors: omoto s. Vaccine. 2022 Jul 30;40(32):4328-4333. doi: 10.1016/j.vaccine.2022.06.032. Epub 2022 Jun 21. Vaccine. 2022. PMID: 35738968 Free PMC article. Clinical Trial.
274 results